CN Patent

CN115087445A — 经皮吸收制剂

Assigned to Sumitomo Pharma Co Ltd · Expires 2022-09-20 · 4y expired

What this patent protects

本发明涉及经皮吸收制剂，其能够维持足以发挥坦度螺酮药效的血药浓度，并且对热、湿度和光的保存稳定性也良好。根据本发明，可以提供坦度螺酮经皮吸收制剂，其特征在于，含有坦度螺酮或其药学上可接受的盐和乙酰丙酸，其中，制剂中的坦度螺酮或其药学上可接受的盐的皮肤透过性优异、且对热、光的保存稳定性良好。

USPTO Abstract

本发明涉及经皮吸收制剂，其能够维持足以发挥坦度螺酮药效的血药浓度，并且对热、湿度和光的保存稳定性也良好。根据本发明，可以提供坦度螺酮经皮吸收制剂，其特征在于，含有坦度螺酮或其药学上可接受的盐和乙酰丙酸，其中，制剂中的坦度螺酮或其药学上可接受的盐的皮肤透过性优异、且对热、光的保存稳定性良好。

Drugs covered by this patent

Patent Metadata

Patent number
CN115087445A
Jurisdiction
CN
Classification
—
Expires
2022-09-20
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.